FibroGen, Inc. — Form 10-Q Summary
Filing identity: The request metadata names Kyntra Bio, Inc., but the supplied filing is for FibroGen, Inc. (Nasdaq: FGEN). This summary reflects the filing provided. Reporting period ended June 30, 2023; financial statements are unaudited.
Business context
FibroGen is a biopharmaceutical company developing pamrevlumab and commercializing roxadustat in China and other approved markets. Roxadustat is approved for chronic kidney disease anemia in China, Europe, Japan and other countries; pamrevlumab is in late-stage trials for pancreatic cancer and Duchenne muscular dystrophy (DMD). The company reported one operating segment.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $44.3 million | $29.8 million | $80.5 million | $90.6 million |
| Operating costs and expenses | $132.4 million | $108.0 million | $244.6 million | $231.8 million |
| Operating loss | $88.0 million | $78.2 million | $164.1 million | $141.2 million |
| Net loss | $87.7 million | $72.6 million | $164.4 million | $135.8 million |
| Basic and diluted loss per share | $0.90 | $0.78 | $1.71 | $1.46 |
- Q2 revenue rose 49%, driven principally by a $13.2 million increase in drug-product revenue from Astellas API shipments; China net product revenue increased 3% to $23.9 million. First-half revenue fell 11%, chiefly reflecting the absence of a $25.0 million Russian approval milestone recognized in Q1 2022 and lower collaboration development revenue.
- Q2 R&D expense rose 35% to $95.5 million, including a one-time, non-cash $24.6 million acquired in-process R&D charge related to Fortis/FG-3246. First-half R&D rose 6% to $170.0 million. SG&A increased 3% in Q2 and 8% for the first half.
- Cash used in operating activities was $212.2 million for the first half, versus $41.5 million in 2022. The 2023 outflow included substantial working-capital movements, including payments and reclassifications related to API and bulk drug-product price true-ups. Investing activities provided $89.2 million, and financing activities provided $123.0 million.
- At June 30, cash and cash equivalents were $152.6 million, short-term investments $183.1 million, and accounts receivable $25.6 million. Together these were $361.3 million, down $81.3 million from year-end. Total current assets were $411.4 million against current liabilities of $194.1 million.
- FibroGen drew a $75 million senior secured term loan, recorded at $71.4 million net of costs. It bears 14% stated interest (16.1% effective annual rate), matures May 2026, and requires at least $30 million of unrestricted U.S. cash; the company reported covenant compliance. A separate revenue-interest financing liability was $52.9 million, including $4.5 million classified current.
- Stockholders’ deficit attributable to FibroGen was $102.3 million. The company sold 2.47 million shares through its ATM program in the first half for $48.4 million net proceeds.
Material changes, outlook and risks
- Clinical results: Pamrevlumab Phase 3 ZEPHYRUS-1 in idiopathic pulmonary fibrosis missed its primary FVC endpoint and a secondary disease-progression endpoint; the company discontinued ZEPHYRUS-2. LELANTOS-1 in non-ambulatory DMD also missed its primary and secondary endpoints. Both trials were described as generally safe and well tolerated. By contrast, ambulatory DMD LELANTOS-2 data were expected in August 2023.
- Near-term trial milestones: Topline results from the LAPIS Phase 3 locally advanced pancreatic cancer trial were expected in Q1 2024; results from the metastatic pancreatic cancer study were expected in the first half of 2024. FibroGen planned a PET-biomarker-driven FG-3246 Phase 2 trial in metastatic castration-resistant prostate cancer for the second half of 2024. Roxadustat’s China Phase 3 chemotherapy-induced anemia study reported positive topline non-inferiority results, and a supplemental application was submitted to China’s health authority.
- Commercial update: Management reported China roxadustat sales volume up more than 40% year over year in Q2 2023, and approximately 39% value share in the cited CKD anemia treatment segment as of May 2023. China reimbursement pricing was due for renegotiation after December 31, 2023.
- Liquidity outlook: Management said available cash, investments, receivables, financing proceeds and implemented cost savings were expected to fund anticipated needs for at least 12 months from issuance of the statements. It also anticipated continued losses and substantial additional funding needs thereafter; forecasts could prove incorrect.
- Restructuring and leadership: A July 14, 2023 plan, subsequent to quarter-end, targeted an approximately 32% reduction in the U.S. workforce, with estimated one-time costs of $13–15 million, mostly expected in Q3 2023. Implementation and cash payments were expected to be substantially complete by Q1 2024. Thane Wettig became interim CEO in July after Enrique Conterno resigned.
- Financing and dilution: The initial $75 million loan was funded, but the $37.5 million milestone-based delayed draw was not available because the clinical milestones were not achieved. A further $37.5 million delayed draw was at the lenders’ discretion. The ATM program authorized up to $200 million in aggregate share sales.
- Legal and operational exposures: The company disclosed securities class-action and derivative litigation, an SEC investigation concerning roxadustat cardiovascular safety data, and Chinese patent challenges; it recorded no material legal accrual because outcomes or exposure could not be estimated. It also disclosed notice during Q3 of a service-provider-related breach involving some pseudonymized clinical data; the initial assessment found no personal identifying information or business-continuity impact, but future impact remained uncertain.
- Other obligations: Non-cancelable purchase commitments totaled $40.8 million, operating lease liabilities $84.8 million, and potential future milestone payments under certain licenses up to approximately $697.9 million, contingent on specified achievements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is FibroGen, not Kyntra Bio.
- Track upcoming pamrevlumab trial readouts and any further development decisions following the negative ZEPHYRUS-1 and LELANTOS-1 results.
- Monitor operating cash use, cash runway, restructuring savings and costs, and whether additional financing is required.
- Review debt terms, cash covenant compliance, delayed-draw availability, and the economic burden of the NovaQuest revenue-interest arrangement.
- Assess China roxadustat sales, reimbursement-price negotiations, competitive/generic developments, and partner-related revenue concentration.
- Follow the securities litigation, SEC investigation, patent proceedings, and the scope and consequences of the reported data incident.